DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DIGIFAB

« Back to Dashboard

All Clinical Trials for DIGIFAB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03810417	Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI	Not yet recruiting	University of Maryland	Phase 4	2019-03-01	Acute kidney injury (AKI) occurs in up to 30% of patients undergoing coronary artery bypass graft (CABG) surgery, and often requires patients to go on dialysis. In patients needing dialysis, the risk of dying is very high.There are no known therapies to reduce the chance of developing kidney damage after heart surgery. There is evidence that patients with high levels of a substance called ouabain have an increased risk of developing kidney damage. This study is testing the hypothesis that giving a medication called DigiFab to lower the ouabain levels will reduce the risk of developing kidney damage after heart surgery.

Clinical Trial Conditions for DIGIFAB

Condition Name

Condition Name for DIGIFAB
Intervention	Trials
Acute Kidney Injury	1

Condition MeSH

Condition MeSH for DIGIFAB
Intervention	Trials
Acute Kidney Injury	1

Clinical Trial Progress for DIGIFAB

Clinical Trial Phase

Clinical Trial Phase for DIGIFAB
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for DIGIFAB
Clinical Trial Phase	Trials
Not yet recruiting	1

Clinical Trial Sponsors for DIGIFAB

Sponsor Name

Sponsor Name for DIGIFAB
Sponsor	Trials
University of Maryland	1

Sponsor Type

Sponsor Type for DIGIFAB
Sponsor	Trials
Other	1